| 1.39 0.02 (1.46%) | 11-28 14:50 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.63 | 1-year : | 1.9 |
| Resists | First : | 1.39 | Second : | 1.63 |
| Pivot price | 1.28  |
|||
| Supports | First : | 1.17 | Second : | 1.03 |
| MAs | MA(5) : | 1.35 |
MA(20) : | 1.28 |
| MA(100) : | 1.38  |
MA(250) : | 1.43 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 94.4 |
D(3) : | 89.1 |
| RSI | RSI(14): 61.6 |
|||
| 52-week | High : | 2 | Low : | 1.03 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ LUCD ] has closed below upper band by 20.1%. Bollinger Bands are 56.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.39 | 1.39 - 1.4 |
| Low: | 1.31 - 1.32 | 1.32 - 1.33 |
| Close: | 1.36 - 1.37 | 1.37 - 1.38 |
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Thu, 16 Nov 2023
Lucid Diagnostics Strengthens and Expands Market Access and ... - PR Newswire
Thu, 16 Nov 2023
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q3 2023 Earnings Call Transcript - Yahoo Finance
Thu, 09 Nov 2023
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day - Yahoo Finance
Thu, 02 Nov 2023
Lucid Diagnostics to Present at Canaccord Genuity Medtech ... - PR Newswire
Wed, 01 Nov 2023
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023 - Yahoo Finance
Thu, 21 Sep 2023
PAVmed and Lucid Diagnostics to Participate in Panel Presentation ... - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 1.15e+007 (%) |
| Held by Institutions | 75.8 (%) |
| Shares Short | 99 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.944e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 421.2 % |
| Return on Equity (ttm) | -90.7 % |
| Qtrly Rev. Growth | 1.5e+006 % |
| Gross Profit (p.s.) | 513.97 |
| Sales Per Share | -208.46 |
| EBITDA (p.s.) | -1.79006e+006 |
| Qtrly Earnings Growth | -1.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -9.61 |
| Dividend | 0 |
| Forward Dividend | 108740 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|